Long-term response to olaparib in a patient with metastatic pancreatic cancer associated with hereditary breast and ovarian cancer syndrome

Michiko Tsuneizumi; Shuzo Terada; Takeshi Usui; Kei Yamaguchi; Ryosuke Hayami; Ryoichi Matsunuma

doi:10.1093/omcr/omac124

Long-term response to olaparib in a patient with metastatic pancreatic cancer associated with hereditary breast and ovarian cancer syndrome

Oxf Med Case Reports. 2022 Nov 24;2022(11):omac124. doi: 10.1093/omcr/omac124. eCollection 2022 Nov.

Authors

Michiko Tsuneizumi^{1

2}, Shuzo Terada³, Takeshi Usui², Kei Yamaguchi¹, Ryosuke Hayami¹, Ryoichi Matsunuma¹

Affiliations

¹ Department of Breast Surgery, Shizuoka General Hospital, Shizuoka 420-8527, Japan.
² Department of Medical Genetics, Shizuoka General Hospital, Shizuoka 420-8527, Japan.
³ Department of Gastroenterology, Shizuoka General Hospital, Shizuoka 420-8527, Japan.

Abstract

BRCA mutations are associated with an increased risk of pancreatic cancer (PC). Olaparib, an oral poly (adenosine diphosphate-ribose) polymerase (PARP) inhibitor, has been approved for the treatment of metastatic PC with a germline BRCA mutation. In this report, we present the case of a metastatic PC harboring a germline BRCA2 mutation, and the daughter of the patient, who had bilateral breast cancers harboring the same germline mutation, suggesting that the PC was associated with hereditary breast and ovarian cancer syndrome. Although PC is an aggressive disease and has poor prognosis, olaparib was administered as maintenance therapy following modified FOLFIRINOX, providing clinical benefits for >12 months.

Publication types

Case Reports